STOCK TITAN
  1. Home
  2. Sec-filings
  3. SLS
  4. [EFFECT] SELLAS Life Sciences Group, Inc. SEC Filing

[EFFECT] SELLAS Life Sciences Group, Inc. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: November 25, 2025 5:00 P.M.
Form: S-3
CIK: 0001390478
Company Name: SELLAS Life Sciences Group, Inc.
File Number: 333-290829

Source: View Original Filing on SEC EDGAR

Stock SLS logo
Sellas Life Sciences Group Inc

NASDAQ:SLS

SLS Rankings

#3152 Ranked by Market Cap
N/A Ranked by Dividends

SLS Latest News

Jan 14, 2026
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
Dec 29, 2025
SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)
Dec 7, 2025
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
Nov 12, 2025
SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 3, 2025
SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting

SLS Latest SEC Filings

Dec 5, 2025
[Form 4] SELLAS Life Sciences Group, Inc. Insider Trading Activity
Nov 21, 2025
[Form 4] SELLAS Life Sciences Group, Inc. Insider Trading Activity
Nov 12, 2025
[8-K] SELLAS Life Sciences Group, Inc. Reports Material Event
Nov 12, 2025
[10-Q] SELLAS Life Sciences Group, Inc. Quarterly Earnings Report
Oct 27, 2025
[424B5] SELLAS Life Sciences Group, Inc. Prospectus Supplement (Debt Securities)

SLS Stock Data

706.67M
142.07M
0.32%
25.55%
27.87%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEW YORK